November 2020

CorLog Probe 1P in times of COVID-19

emka MEDICAL GmbH has developed an innovative technology for measuring invasive pressures. The focus is on measuring blood pressures. The main goal of using this technology is to monitor and adapt therapy for general heart failure. On the way there, emka MEDICAL is also exploring other applications such as structural heart diseases (tricuspid valve insufficiency), cardiac support systems and pulmonary arterial hypertension (PAH). The development goes from short-term applications of up to 30 days to long-term applications in which CorLog is implanted.

In the future, CorLog Probe 1P could also play a role in the fight against COVID-19. COVID-19 often increases the flow resistance of the lungs and thus the pressure (pulmonary artery pressure), see figure 1. According to guidelines for pulmonary arterial hypertension (PAH), this should be examined with a right heart catheterization. This complex procedure, which is also stressful for the heart valves, only provides one-time information. Using CorLog Probe 1P not only saves you this procedure, you also get continuous and mobile pressure values of up to 30 days. These pressures can then be used to adjust pharmaceutical therapy to bring PAH under control.

Figure 1: COVID-19 effects that can lead to pulmonary hypertension and right heart failure [1].

Pulmonary hypertension [1] can also damage the right ventricle [3] [4] and cause right heart failure [1] [2]. Both pulmonary hypertension and changes in the right ventricle can be measured using CorLog [5], see also figure 2.

Figure 2: Right ventricular pressure (black) and part of the curve that is common with pulmonary artery pressure (red). Localization of the area with the help of the first time derivative of the pressure.

In contrast to other solutions, patients can be mobilized with CorLog. This can be used to carry out stress tests which can be monitored wirelessly with CorLog.

The use of CorLog for severe courses of COVID-19 with pulmonary hypertension is currently being investigated by intensive care physicians. Publications are planned.


[1] Park JF, Banerjee S, Umar S. In the eye of the storm: the right ventricle in COVID-19. Pulm Circ. 2020;10(3):2045894020936660. Published 2020 Jul 2. doi:10.1177/2045894020936660

[2] Argulian E, Sud K, Vogel B, et al. Right Ventricular Dilation in Hospitalized Patients with COVID-19 Infection [published online ahead of print, 2020 May 15]. JACC Cardiovasc Imaging. 2020;10.1016/j.jcmg.2020.05.010. doi:10.1016/j.jcmg.2020.05.010

[3] Basso C, Leone O, Rizzo S, et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J. 2020;41(39):3827-3835. doi:10.1093/eurheartj/ehaa664

[4] Li Y, Li H, Zhu S, et al. Prognostic Value of Right Ventricular Longitudinal Strain in Patients With COVID-19 [published online ahead of print, 2020 Apr 28].JACC Cardiovasc Imaging. 2020;S1936-878X(20)30342-9. doi:10.1016/j.jcmg.2020.04.014

[5] Karamanoglu M, Bennett T, Ståhlberg M, et al. Estimation of cardiac output in patients with congestive heart failure by analysis of right ventricular pressure waveforms. Biomed Eng Online. 2011;10:36. Published 2011 May 13. doi:10.1186/1475-925X-10-36

September 2020

90 days preclinical study ended on Sept. 8, detailed examinations in process, these picture upfront.

August 2020

CorLog Probe 1P has been successfully used in ten patients in three different hospitals across Germany. Hemodynamic state changes of different surgical and transcatheter based procedures were recorded.

Compare waveforms before and after interventions at different points of time up to 30 days in total:

See the exact moment of intervention and the hemodynamical state change that follows:

First in world mobile, wireless measurement of right atrial pressures during activity of patient:

May/June 2020

emka MEDICAL started a structured preclinical experiment in a validated preclinical lab with referenced measurements (two probes per insertion site, used as implants, altogether 36 probes) for several periods of indwelling times, time lines much above 30 days, and these picture show performances within first days.

Further patient applications with tricuspid interventions got executed in Hamburg also in May, 2020, results to be reserved for planned publications of the cardiologists in charge.

March 2020

CorLog Probe 1P for assist pressure monitoring (at axial heart pump hear assist) got CE marked March 19, as medical device of class IIa, for right atrium pressure monitoring (then class III) emka MEDICAL has started application for a clinical trial along ISO 14155 at BfArM. Still clinical data will be collected through pathway EU-MDR-Annex XIII, custom-made devices, to evaluate CE conformity for the jugular venous pressure sensing application, in such case CorLlog Probe 1P will be medical device of class IIb.

The DGK congress April 15-18 got cancelled, we will not exhibit, but we got an advertorial about CorLog Probe 1P in “Spitzenforschung Herz-Kreislauf-Medizin 2020” related to DGK, will be visible on our NEWS soon.

January 2020

Prof. Schofer’s lecture about functional monitoring of clipped tricuspid valves got accepted for annual congress of German Cardiac Society, April 15-18, in Mannheim. We are proud that we were able to contribute devices and data analysis, the abstract for this lecture can be found here.

December 2019

We will exhibit on the DKG congress 2020 in Mannheim from April 15 to April 18, congress subject “the multimorbid heart patient” fits to our mobile monitoring capabilities of Cor/log Probe 1P.

Prof. Schofer, Hamburg, has submitted a lecture about „First wireless right atrial pressure measurement in patients with severe tricuspid regurgitation before and after percutaneous or surgical treatment“, Abstract will be available after acceptance by DGK here on the NEWS as link. That relates to the October 2019 NEWS with picture of a used Cor/log Probe 1P.

Our DGK booth number will be: 026, Level -1.

October 2019

Cor/log Probe 1P got successfully used in human applications in two different clinical sites in September and October. Both clinical partners are preparing publications so emka MEDICAL is waiting with further presentations until publication.

For now we can present you a photo of one used Cor/log Probe 1P after an indwelling time of one week.

June 2019

Successful in-vivo experiment in May 2019. Two Cor/log Probe 1P were implanted into a freely moving pig. Zero drift of the pressure baseline over 29 days. Measurement of S1 and S2 heart sounds due to high frequency resolution of the probe. This can be used to identify the a- and v-wave of the central venous pressure which can be used to diagnose tricuspid valve regurgitation. Continuous data transfer during this time to Cor/log Connect and Cor/log App.

May 2019

We will be presenting our Cor/log System at the Hamburg Heart Days 2019 from 17 to 18 May. You can visit us at booth 22 in the tent. We are excited to talk to you about monitoring of structural heart diseases in the right heart.